Tumor hormone receptor status and recurrences in premenopausal node negative breast carcinoma

Sally K. Moot, George N. Peters, J. Harold Cheek

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

To ascertain the prognostic significance of tumor hormone receptor status in node negative, premenopausal patients with breast cancer, a retrospective view of 199 patients fitting these criteria was conducted. Of these 199 patients, 147 had estrogen receptor data available. There were 104 patients (71%) who were estrogen receptor negative, and 16 (15%) had developed local or distant recurrence with a median follow‐up of 44 months. Five patients had died of breast cancer. Of the 43 patients who were estrogen receptor positive, there was one recurrence, and no breast cancer deaths. This difference in recurrence is statistically significant (P < 0.01) by the log‐rank probability test. Of the 17 patients with recurrent disease, 14 (82%) had primary tumors 2 cm or larger in size. If only those patients with tumors 2 cm or larger are considered, 23% (13/57) who were estrogen receptor negative and 5% (1/19) who were estrogen receptor positive recurred. This remains statistically significant (P < 0.025). We conclude that tumor hormone receptor status and size of tumor are significant prognostic factors in identifying premenopausal, node negative women at risk for recurrent disease.

Original languageEnglish (US)
Pages (from-to)382-385
Number of pages4
JournalCancer
Volume60
Issue number3
DOIs
StatePublished - Jan 1 1987

Fingerprint

Hormones
Breast Neoplasms
Recurrence
Estrogen Receptors
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tumor hormone receptor status and recurrences in premenopausal node negative breast carcinoma. / Moot, Sally K.; Peters, George N.; Cheek, J. Harold.

In: Cancer, Vol. 60, No. 3, 01.01.1987, p. 382-385.

Research output: Contribution to journalArticle

Moot, Sally K. ; Peters, George N. ; Cheek, J. Harold. / Tumor hormone receptor status and recurrences in premenopausal node negative breast carcinoma. In: Cancer. 1987 ; Vol. 60, No. 3. pp. 382-385.
@article{8f534d1e7b8943d3aa164b31f2550ba9,
title = "Tumor hormone receptor status and recurrences in premenopausal node negative breast carcinoma",
abstract = "To ascertain the prognostic significance of tumor hormone receptor status in node negative, premenopausal patients with breast cancer, a retrospective view of 199 patients fitting these criteria was conducted. Of these 199 patients, 147 had estrogen receptor data available. There were 104 patients (71{\%}) who were estrogen receptor negative, and 16 (15{\%}) had developed local or distant recurrence with a median follow‐up of 44 months. Five patients had died of breast cancer. Of the 43 patients who were estrogen receptor positive, there was one recurrence, and no breast cancer deaths. This difference in recurrence is statistically significant (P < 0.01) by the log‐rank probability test. Of the 17 patients with recurrent disease, 14 (82{\%}) had primary tumors 2 cm or larger in size. If only those patients with tumors 2 cm or larger are considered, 23{\%} (13/57) who were estrogen receptor negative and 5{\%} (1/19) who were estrogen receptor positive recurred. This remains statistically significant (P < 0.025). We conclude that tumor hormone receptor status and size of tumor are significant prognostic factors in identifying premenopausal, node negative women at risk for recurrent disease.",
author = "Moot, {Sally K.} and Peters, {George N.} and Cheek, {J. Harold}",
year = "1987",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19870801)60:3<382::AID-CNCR2820600316>3.0.CO;2-J",
language = "English (US)",
volume = "60",
pages = "382--385",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Tumor hormone receptor status and recurrences in premenopausal node negative breast carcinoma

AU - Moot, Sally K.

AU - Peters, George N.

AU - Cheek, J. Harold

PY - 1987/1/1

Y1 - 1987/1/1

N2 - To ascertain the prognostic significance of tumor hormone receptor status in node negative, premenopausal patients with breast cancer, a retrospective view of 199 patients fitting these criteria was conducted. Of these 199 patients, 147 had estrogen receptor data available. There were 104 patients (71%) who were estrogen receptor negative, and 16 (15%) had developed local or distant recurrence with a median follow‐up of 44 months. Five patients had died of breast cancer. Of the 43 patients who were estrogen receptor positive, there was one recurrence, and no breast cancer deaths. This difference in recurrence is statistically significant (P < 0.01) by the log‐rank probability test. Of the 17 patients with recurrent disease, 14 (82%) had primary tumors 2 cm or larger in size. If only those patients with tumors 2 cm or larger are considered, 23% (13/57) who were estrogen receptor negative and 5% (1/19) who were estrogen receptor positive recurred. This remains statistically significant (P < 0.025). We conclude that tumor hormone receptor status and size of tumor are significant prognostic factors in identifying premenopausal, node negative women at risk for recurrent disease.

AB - To ascertain the prognostic significance of tumor hormone receptor status in node negative, premenopausal patients with breast cancer, a retrospective view of 199 patients fitting these criteria was conducted. Of these 199 patients, 147 had estrogen receptor data available. There were 104 patients (71%) who were estrogen receptor negative, and 16 (15%) had developed local or distant recurrence with a median follow‐up of 44 months. Five patients had died of breast cancer. Of the 43 patients who were estrogen receptor positive, there was one recurrence, and no breast cancer deaths. This difference in recurrence is statistically significant (P < 0.01) by the log‐rank probability test. Of the 17 patients with recurrent disease, 14 (82%) had primary tumors 2 cm or larger in size. If only those patients with tumors 2 cm or larger are considered, 23% (13/57) who were estrogen receptor negative and 5% (1/19) who were estrogen receptor positive recurred. This remains statistically significant (P < 0.025). We conclude that tumor hormone receptor status and size of tumor are significant prognostic factors in identifying premenopausal, node negative women at risk for recurrent disease.

UR - http://www.scopus.com/inward/record.url?scp=0023199247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023199247&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19870801)60:3<382::AID-CNCR2820600316>3.0.CO;2-J

DO - 10.1002/1097-0142(19870801)60:3<382::AID-CNCR2820600316>3.0.CO;2-J

M3 - Article

C2 - 3594374

AN - SCOPUS:0023199247

VL - 60

SP - 382

EP - 385

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -